Study of Subcutaneous and Intravenous Velcade in Combination With Dexamethasone in Chinese Subjects With Relapsed and Refractory Multiple Myeloma

Inclusion Criteria:

• Have received at least 1 and no more than 3 prior lines of therapy for multiplemyeloma

• Have an Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2

• The toxicities resulting from previous therapy must be resolved or stabilized to lessthan or equal (<=)Grade 1 prior to drug administration

• A woman of childbearing potential must have a negative highly sensitive serum (humanchorionic gonadotropin [hCG]) or urine pregnancy tests at screening within 14 daysprior to Cycle 1 Day 1

• Have documented evidence of progressive disease/disease progression based oninvestigator's determination of response by the International Myeloma Working Group (IMWG) criteria on or after their last regimen

Exclusion Criteria:

• Received antimyeloma treatment within 2 weeks or 5 pharmacokinetic half-lives of thetreatment, whichever is longer, before the date of randomization. The only exceptionis emergency use of a short course of corticosteroids (equivalent of dexamethasone 40milligram per day (mg/day) for a maximum of 4 days) before treatment.

• Received autologous stem cell transplant (ASCT) within 12 weeks before the date ofrandomization, or the participant has previously received an allogenic stem celltransplant (regardless of timing)

• Plans to undergo a stem cell transplant prior to progression of disease on this study,that is, these participants should not be enrolled in order to reduce disease burdenprior to transplant

• Is known to be infected with human immunodeficiency virus (HIV) or active infectionwith hepatitis B or hepatitis C

• Had myocardial infarction within 6 months prior to enrollment or has New York HeartAssociation (NYHA) Class III or IV heart failure, uncontrolled angina, severeuncontrolled ventricular arrhythmias, or electrocardiographic evidence of acuteischemia or clinically significant conduction system abnormalities